EKF Diagnostics, the diabetes point of care diagnostics company, announced that its Quotient Diagnostics subsidiary (acquired in October 2010) has gained marketing approval for its Quo-Test point of care Hb1AC (glycated haemoglobin) test from the Safety for Food and Drug Administration (SFDA) in China. Quotient's Chinese partner, Shanghai Upper Biotech is expected to receive the license within the next two weeks. Following this, promotion and selling of the tests can begin.

The Chinese market for diabetes diagnostics is expected to grow quickly in importance after a 2010 study in the New England Journal of Medicine suggested that up to 10% of the Chinese population may have diabetes (a similar percentage to the US). The rapid economic growth in China has brought about diet and lifestyle changes that are thought to contribute to the prevalence of the disease.

EKF also announced that it has received the cash payments (a total of about £720,000) from the sale of the Admiral trademarks in the Americas and Europe.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here